Allarta Life Science

Allarta Life Science is a pre-clinical stage life science company, with a proprietary platform technology to enable curative cell treatments for endocrine disorders such as Lysosomal Storage Disorders/Orphan Diseases, Diabetes and Hemophilia. Allarta is raising a Pre-Series A Bridge financing to support pre-clinical studies (diabetes), determining path to Orphan Drug cell models for small and large animal studies, and R&D investment on pipeline IP and core technologies within the company.

Presenter: Harald Stover, Co-Founder & CEO

Mediphage Bioceuticals

Mediphage Bioceuticals, a preclinical-stage biotechnology company, is developing the next-generation non-viral gene delivery platform based on its ministring DNA (msDNA) technology. Mediphage’s proprietary msDNA is a versatile gene delivery platform that has the potential for applications in various therapeutic areas including retina, liver, oncology, and CNS disorders among others. msDNA can be used in applications beyond gene therapy, including DNA vaccines to address infectious diseases, improved rAAV platform production, and gene editing. Mediphage is currently raising $32M CAD in Series A which will support executive and technical team growth, process development and proof of concept studies.

Presenter: Alvaro Amorrortu, CEO & President

Mesentech

Mesentech makes bi-specific small-molecule therapeutics that are selective for both a tissue target and a molecular target. These chemical conjugates liberate the active pharmaceutical only in the targeted tissue thereby eliminating side effects caused by systemic exposure. Mesentech’s lead program is a bone-targeted anabolic that stimulates bone regeneration. It is indicated for severe pediatric osteoporosis caused by brittle bone disease, Duchenne muscular dystrophy and as a consequence of steroid treatment.

Presenter: Jonathan Polak, CEO

Regenerative Medicine, Therapeutic Platform, Metabolic DiseasesDonald CudmoreJanuary 5, 2021

Zucara Therapeutics Inc.

Zucara Therapeutics Inc. is developing ZT-01, a first-in-class, once-daily therapeutic to prevent insulin-induced hypoglycemia in patients using insulin therapy. ZT-01 is designed to inhibit somatostatin, a pancreatic hormone that impairs the glucagon response to hypoglycemia in people with insulin dependent diabetes. ZT-01 restores glucagon secretion to prevent hypoglycemia, which could dramatically change diabetes disease management and improve both patient health and quality of life. Zucara has recently raised US$21M in a Series A financing that provides capital to conduct Phase 1 and 2 clinical trials. Phase 1 trials are underway with results expected in 2021. For more information, visit www.zucara.ca.

Presenter: Michael Midmer, CEO

Metabolic DiseasesDonald CudmoreJanuary 5, 2021